LLY241129P740000
- 0.01
- -0.07-87.50%
Eli Lilly and Co Newsroom
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
S&P 500 Posts Weekly Rise to Fresh Record, Ends November With Strongest Monthly Gain of Year
10 Health Care Stocks With Whale Alerts In Today's Session
Behind the Scenes of Eli Lilly's Latest Options Trends
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Eli Lilly's Flortaucipir Approved by UK Regulator to Test for Alzheimer's Disease
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
Express News | Mhra: Approves Flortaucipir (Tauvid) for Adults Showing Signs of Cognitive Impairment for Alzheimer’s Disease
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
Top Gap Ups and Downs on Tuesday: LLY, ZM, BBY and More
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Eli Lilly and Co (LLY.US) cancels double injections, brewing super BD for muscle gain and fat loss.
GLP-1 dual heroes Semaglutide and Tirzepatide, the total sales in 2024 will exceed $40 billion, leading to a huge demand in the muscle-building drug market.
U.S. stocks closed: The Dow and S&P reached all-time highs, while general motors plunged nearly 9%.
① Most technology giants rose, only Tesla fell; ② Eli Lilly and Co rose by 4.5%, as Biden proposed health insurance coverage for weight loss drugs; ③ The Chinese concept stock Jinlong Index fell by 0.8%, Nio fell by 7.7%; ④ Apple proposed to increase investment by 0.1 billion US dollars to seek to lift the sales ban, but was rejected by the Indonesian government.
Eli Lilly and Co Options Spot-On: On November 26th, 120.59K Contracts Were Traded, With 340.93K Open Interest